MUTYH and pachyonychia congenita: Our novel work has identified MYH as a potential therapeutic target for PC that can (i) decrease PC cell survival, (ii) improve the efficacy of existing therapeutics, including first-line treatments for PC (gemcitabine/paclitaxel) and (iii) reduce the metastatic potential of PC cells.